InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Explore the detailed record of transactions filed by Kim Christopher. Director active across 1 company, notably Apimeds Pharmaceuticals US, Inc.. Aggregated, 2 filings have been published. Split: 1 buy · 0 sell. Total volume traded: €32k. Activity tracked since 13 May 2025. The latest transaction was disclosed on 16 May 2025 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
2 of 2 declarations